Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
NCT06171750
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- Cutaneous Tumor
- Subcutaneous Tumor
- Malignant Solid Tumor
- Solid Tumor
- Metastatic Solid Tumor
- Metastasis to Soft Tissue
- Non Small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Ankyra Therapeutics, Inc
- Last updated on ClinicalTrials.gov
- March 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- National Cancer Institute · Bethesda, MD
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Oregon · 1
- Providence Cancer Institute · Portland, OR
Pennsylvania · 1
- Hillman Cancer Center · Pittsburgh, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.